Sai Life Sciences

Sai Life Sciences

866.25
-16.35
(-1.85%)
hide
Key Fundamentals
Add Ratio
Market Cap
18,468.30 Cr
EPS
8.83
PE Ratio
74.27
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
943.00
52 Week Low
636.10
PB Ratio
8.51
Debt to Equity
0.41
Analyst Rating and Forecast
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Sai Life Sciences opened Unit VI, a dedicated facility for veterinary API production, in Bidar, India on September 18, 2025. The facility is located alongside Unit IV, the company's flagship API manufacturing site. The new facility is designed to meet high standards of safety, sustainability, and regulatory compliance for producing veterinary APIs. The expansion aims to provide scalable manufacturing solutions to global animal health companies. CEO Krishna Kanumuri stated the investment strengthens the company's ability to meet growing global demand for veterinary pharmaceuticals while maintaining standards of innovation, efficiency, and sustainability. The facility leverages advanced technologies and supply chain management for reliable manufacturing of animal health APIs.
positive
SAI Life Sciences has completed Phase II of its Production Block 11 facility in Bidar, India. The completion has increased the company's production capacity to 700 KL.
positive
Goldman Sachs acquired 1.1 million shares of Sai Lifescience through open market transactions. Societe Generale acquired 1.4 million shares of the company through similar open market transactions.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,654.70
#1 3,91,379.50
34.59
#1 54,729.00
9.71
#1 10,980
-19.84
53.70
5,826.50
1,55,723.90
67.06
9,712.00
18.67
2,191
26.74
42.63
1,513.10
1,22,592.80
22.67
28,409.50
7.12
5,291
9.88
44.34
3,526.00
1,18,953.40
59.08
11,539.40
6.99
1,911
19.91
41.67
1,248.60
1,04,168.10
#1 18.34
33,741.20
16.73
5,725
1.26
42.92
2,456.30
1,01,043.30
53.53
12,744.20
#1 20.90
2,007
-18.14
37.12
994.65
99,446.10
21.46
23,511.00
18.55
4,615
2.60
42.93
1,937.30
90,145.10
23.93
22,909.50
13.74
3,306
#1 51.64
50.36
5,494.00
65,067.30
28.86
13,458.30
3.70
2,216
21.39
53.98
30,020.00
63,673.50
43.95
6,684.70
9.64
1,414
11.55
38.08
Growth Rate
Revenue Growth
15.86 %
Net Income Growth
105.43 %
Cash Flow Change
19.37 %
ROE
-5.89 %
ROCE
-1.49 %
EBITDA Margin (Avg.)
21.38 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
395
443
288
406
449
589
506
Expenses
287
315
254
293
320
422
376
EBITDA
108
128
34
112
129
167
131
Operating Profit %
25 %
28 %
9 %
26 %
27 %
27 %
24 %
Depreciation
31
31
31
36
34
38
38
Interest
23
21
21
21
23
11
12
Profit Before Tax
53
76
-18
55
72
119
81
Tax
13
20
-5
14
18
31
20
Net Profit
40
56
-14
42
54
88
61
EPS in ₹
2.19
31.00
-0.74
2.22
2.89
4.24
2.90

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
1,410
1,817
2,157
2,187
2,275
3,160
Fixed Assets
641
753
751
1,037
1,180
1,488
Current Assets
613
804
944
964
945
1,505
Capital Work in Progress
91
194
410
151
107
125
Investments
0
0
0
2
2
2
Other Assets
679
870
997
997
987
1,545
Total Liabilities
1,410
1,817
2,157
2,187
2,275
3,160
Current Liabilities
467
599
713
759
740
733
Non Current Liabilities
149
356
565
540
560
299
Total Equity
794
863
879
888
975
2,128
Reserve & Surplus
777
845
861
870
957
2,108
Share Capital
16
18
18
18
18
21

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
239
-150
-1
75
-80
-24
79
Investing Activities
-158
-262
-260
-102
-99
-191
-536
Operating Activities
129
116
-36
105
219
263
314
Financing Activities
268
-4
296
72
-201
-95
301

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
39.64 %
35.24 %
35.24 %
35.17 %
35.15 %
FIIs
0.00 %
7.64 %
11.72 %
12.36 %
14.58 %
DIIs
0.00 %
5.61 %
11.95 %
13.26 %
21.64 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
18.68 %
8.88 %
7.69 %
6.56 %
Others
60.36 %
32.84 %
32.22 %
31.52 %
22.07 %
No of Share Holders
70
5,72,970
82
1,40,677
1,26,380

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 695.75 694.80
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 May 2025 717.70 713.35
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 815.20 792.85
11 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
11 Sept 2025 791.55 861.70

Announcements

Closure of Trading Window7 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 11, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 11, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 11, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 03, 2025
Corrigendum To The Notice Of The 26Th Annual General Meeting.Sep 03, 2025
Company -UpdatesSep 03, 2025
Company-UpdatesSep 02, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 30, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 28, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 19, 2025
Reg. 34 (1) Annual Report.Aug 18, 2025
Notice Of 26Th Annual General Meeting Of The Members Of Sai Life Sciences Limited To Be Held On Thursday 11Th September 2025 At 10.30 A.M. (IST)Aug 18, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Announcement under Regulation 30 (LODR)-Credit RatingAug 14, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Announcement under Regulation 30 (LODR)-Meeting UpdatesAug 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended On 30 June 2025.Aug 07, 2025
Board Meeting Outcome for Board Meeting Outcome For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended On 30 June 2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 23, 2025
Board Meeting Intimation for Notice Of The Board MeetingJul 21, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jul 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Clarification On Increase In VolumeJul 03, 2025
Clarification sought from Sai Life Sciences LtdJul 03, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 27, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 27, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 27, 2025
Closure of Trading WindowJun 25, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 23, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 20, 2025
Intimation For Commencement Of Commercial Operation Of The Second Phase Of The Production - (Unit IV Bidar Facility)Jun 20, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJun 17, 2025
Ratification Of ESOP Scheme And Extension Of Benefits To The Employees Of Its Subsidiaries.Jun 17, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 17, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Invesco India Large & Mid Cap Fund Direct-Growth
4.35%
1156100
1.19%
1.48%
Invesco India Smallcap Fund Direct - Growth
5.28%
1072959
1.15%
2.29%
HSBC Small Cap Fund Direct-Growth
0.95%
852277
0.47%
0.50%
Axis Flexi Cap Fund Direct-Growth
0.72%
765403
0.50%
0.52%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
2.10%
706395
1.26%
1.31%
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth
0.84%
656395
0.84%
0.84%
Axis Small Cap Fund Direct-Growth
1.22%
535782
0.22%
0.53%
Bandhan Small Cap Fund Direct-Growth
0.30%
527523
0.30%
0.30%
Nippon India Multi Cap Fund Direct-Growth
0.63%
486128
0.09%
0.11%
PGIM India Midcap Fund Direct-Growth
0.34%
465116
0.34%
0.34%
PGIM India Flexi Cap Fund Direct-Growth
0.50%
379844
0.50%
0.50%
Invesco India Mid Cap Fund Direct-Growth
3.31%
346800
0.32%
0.56%
Axis Multicap Fund Direct-Growth
0.80%
305134
0.31%
0.33%
HDFC Manufacturing Fund Direct - Growth
0.00%
-284111
-0.19%
-0.18%
ITI Small Cap Fund Direct-Growth
0.83%
263459
0.83%
0.83%
Invesco India Flexi Cap Fund Direct - Growth
1.93%
213172
0.41%
0.40%
Edelweiss Balanced Advantage Fund Direct-Growth
0.11%
177000
0.11%
0.11%
Edelweiss Aggressive Hybrid Fund Direct - Growth
0.48%
177000
0.48%
0.48%
Mirae Asset Multicap Fund Direct - Growth
1.37%
175000
0.38%
0.10%
Invesco India Multicap Fund Direct-Growth
1.83%
171707
0.39%
1.83%
Tata India Pharma & Healthcare Fund Direct-Growth
1.02%
162453
1.02%
1.02%
ITI Mid Cap Fund Direct - Growth
1.01%
147565
1.01%
1.01%
Bandhan Midcap Fund Direct-Growth
1.61%
136914
0.64%
0.67%
ITI Multi Cap Fund Direct - Growth
0.89%
135997
0.89%
0.89%
Edelweiss Recently Listed IPO Fund Direct-Growth
3.84%
130000
1.19%
1.31%

Technical Indicators

RSI(14)
Neutral
52.43
ATR(14)
Less Volatile
26.73
STOCH(9,6)
Neutral
36.48
STOCH RSI(14)
Neutral
25.24
MACD(12,26)
Bearish
-1.86
ADX(14)
Weak Trend
17.18
UO(9)
Bearish
47.48
ROC(12)
Uptrend And Accelerating
0.14
WillR(14)
Neutral
-52.71